- Home
- WD vs SRRK Comparison
WD vs SRRK Comparison
Compare WD & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WD
- SRRK
- Stock Information
- Founded
- WD 1937
- SRRK 2012
- Country
- WD United States
- SRRK United States
- Employees
- WD N/A
- SRRK N/A
- Industry
- WD Finance: Consumer Services
- SRRK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WD Finance
- SRRK Health Care
- Exchange
- WD Nasdaq
- SRRK Nasdaq
- Market Cap
- WD 2.8B
- SRRK 3.0B
- IPO Year
- WD 2010
- SRRK 2018
- Fundamental
- Price
- WD $62.76
- SRRK $39.92
- Analyst Decision
- WD Buy
- SRRK Strong Buy
- Analyst Count
- WD 2
- SRRK 11
- Target Price
- WD $96.00
- SRRK $47.30
- AVG Volume (30 Days)
- WD 232.2K
- SRRK 2.1M
- Earning Date
- WD 11-06-2025
- SRRK 11-14-2025
- Dividend Yield
- WD 4.28%
- SRRK N/A
- EPS Growth
- WD 20.18
- SRRK N/A
- EPS
- WD 3.37
- SRRK N/A
- Revenue
- WD $1,160,070,000.00
- SRRK N/A
- Revenue This Year
- WD $18.92
- SRRK N/A
- Revenue Next Year
- WD $8.31
- SRRK $1,987.65
- P/E Ratio
- WD $18.60
- SRRK N/A
- Revenue Growth
- WD 17.65
- SRRK N/A
- 52 Week Low
- WD $61.25
- SRRK $22.71
- 52 Week High
- WD $114.04
- SRRK $46.98
- Technical
- Relative Strength Index (RSI)
- WD 22.73
- SRRK 70.40
- Support Level
- WD $61.25
- SRRK $29.35
- Resistance Level
- WD $69.19
- SRRK $39.50
- Average True Range (ATR)
- WD 2.52
- SRRK 1.90
- MACD
- WD -1.26
- SRRK 1.40
- Stochastic Oscillator
- WD 7.25
- SRRK 95.98
About WD Walker & Dunlop Inc
Walker & Dunlop Inc is a United States-based commercial real estate finance company. It is principally engaged in originating, selling, and servicing a number of multifamily and other commercial real estate financing products that are sold under the programs of Freddie Mac, Fannie Mae, Ginnie Mae, and the Federal Housing Administration. The company is managed based on three reportable segments: Capital Markets (CM), Servicing & Asset Management (SAM), and Corporate. The company generates a majority of total revenue from gains from mortgage banking activities and servicing fees. It conducts business solely in the United States.
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.